RxDoctor Payments Data

Ian Sherman

Adult Health · Albany, NYNPI 1639682990

Payments from drug & device makers

$9,486in general payments, 2019–2025

Across 673 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$954
  • Pfizer$877
  • SK Life Science, Inc.$741
  • Neurocrine Biosciences, Inc.$562
  • Lilly USA, LLC$447
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$9,20497%
  • Education$2813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,486 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$67,279
Medicare patients
238
Services billed
4,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$140,088
Nurtec OdtRimegepant Sulfate58$109,979
UbrelvyUbrogepant74$86,577
AustedoDeutetrabenazine12$57,631
XcopriCenobamate32$41,683
QuliptaAtogepant24$32,627
NeuproRotigotine31$28,171
Aimovig AutoinjectorErenumab-Aooe13$15,807
Emgality PenGalcanezumab-Gnlm16$11,482
Lacosamide44$5,576
AmantadineAmantadine Hcl77$5,176
Carbamazepine25$4,361
Levetiracetam130$4,248
Carbidopa-LevodopaCarbidopa/Levodopa187$4,230
Levetiracetam ErLevetiracetam28$3,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$562$140,08817 claims
AbbVieUbrelvy, Qulipta$1,720$119,20498 claims
PfizerNurtec Odt$877$109,97958 claims
Teva Pharmaceuticals USA, Inc.Austedo$421$57,63112 claims
SK Life Science, Inc.Xcopri$741$41,68332 claims
UCB, Inc.Neupro$954$28,17131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →